UNCY Stock Analysis: Buy, Sell, or Hold?
UNCY - Unicycive Therapeutics, Inc. Common Stock
$5.40
-0.23 (-4.09%)
▼
5d:
-3.05%
30d:
+0.0%
90d:
-33.17%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: UNCY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: UNCY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $5.40, which is considered extended relative to its 30-day fair value range of $5.03 to $5.52. From a valuation perspective, the stock is trading at a premium (Forward PE: 4.0) compared to its historical average (1.1). At these levels, the market is pricing in 54.4% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, UNCY is in a strong downtrend. Immediate support is located at $4.92, while resistance sits at $5.85. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: UNCY scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.00 (+397.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UNCY is in a strong downtrend. Immediate support is located at $4.92, while resistance sits at $5.85. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: UNCY scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.00 (+397.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.03 -
$5.52
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 397.3% below Wall St target ($28.00)
- BEARISH: Market expects 54.4% growth - appears too optimistic based on history
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.03 -
$5.52
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.92
Resistance Level
$5.85
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.03
Wall Street Target
$28.00
(+397.3%)
Valuation Premium vs History
+54.4% premium
PE vs Historical
4.0 vs 1.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+54.4%
(market-implied from PE analysis)
1-Year Target
$8.45
(+50%)
2-Year Target
$12.67
(+125%)
3-Year Target
$19.00
(+238%)
3-Yr Target (if PE normalizes)
(PE: 4→1)
PE COMPRESSION
$5.19
(-8%)
Significant PE compression expected
Share & Embed Analysis
Last updated: August 24, 2026 10:07 AM ET
Data refreshes hourly during market hours. Next update: 11:07 AM
Data refreshes hourly during market hours. Next update: 11:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
